Skip to main content
SpringerLink
Log in

Prevention of Hepatitis B Virus Infection and Liver Cancer

  • Chapter
  • First Online:
Viruses and Human Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 217))

Abstract

Hepatocellular carcinoma (HCC) is one of the five leading causes of cancer death in human. Hepatitis B virus (HBV) is the most common etiologic agent of HCC in the world. Prevention is the best way to control cancer. There are three levels of liver cancer prevention, i.e., primary prevention by HBV vaccination targeting the general population starting from birth dose, secondary prevention by antiviral agent for high-risk subjects with chronic HBV infection, and tertiary prevention by antiviral agent to prevent recurrence for patients who have been successfully treated for liver cancer. Primary prevention by hepatitis B vaccination is most cost effective, the cancer preventive efficacy support it as the first successful example of cancer preventive vaccine in human. Addition of hepatitis B immunoglobulin immediately after birth and antiviral agent during the third trimester of pregnancy to block mother-to-infant transmission of HBV are existing or possible emerging strategies to enhance the prevention efficacy of HBV infection and its related liver cancer. Secondary prevention with current antiviral agents may reduce the risk or delay the onset of HCC development, but could not eradicate HBV infection and HCC. Better antiviral therapeutic agents are needed for better secondary prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Athuluri-Divakar SK, Hoshida Y. (2018) Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci (17 September, 2018). https://doi.org/10.1111/nyas.13971. Epub ahead of print

  • Beasley RP (1982) Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: epidemiologic considerations. Hepatology 2:21s–26s

    Google Scholar 

  • Beasley RP, Hwang LY, Lin CC et al (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 2:1129–1133

    Article  PubMed  CAS  Google Scholar 

  • Beasley RP, Trepo C, Stevens CE et al (1977) The e antigen and vertical transmission of hepatitis B surface antigen. Amer J Epidemiol 105:94–98

    Article  CAS  Google Scholar 

  • Braitenstein S, Dimitroulis D, Petrowsky H et al (2009) Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 96:975–981

    Article  CAS  Google Scholar 

  • Bosch FX, Ribes J (2002) The epidemiology of primary liver cancer: global epidemiology. In: Tabor E (ed) Viruses and liver cancer. Elsevier Science, Amsterdam, pp 1–16

    Google Scholar 

  • Bruix J, Boix L, Sala M et al (2004) Focus on hepatocellular carcinoma. Cancer Cell 5:215–219

    Article  PubMed  CAS  Google Scholar 

  • Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. AASLD Guideline recommendations for HCC screening, Hepatology 42:1208–1236

    Google Scholar 

  • Cammà C, Giunta M, Andreone P et al (2001) Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34:593–602

    Article  PubMed  Google Scholar 

  • Chang MH (2013) Paediatrics: Children need optimal management of chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 10:505–506

    Article  PubMed  Google Scholar 

  • Chang MH, Chen CJ, Lai MS et al (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336:1855–1859

    Article  PubMed  CAS  Google Scholar 

  • Chang MH, Chen DS, Hsu HC et al (1989) Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 64:2377–2380

    Article  PubMed  CAS  Google Scholar 

  • Chang MH, Chen PJ, Chen JY et al (1991) Hepatitis B virus integration in hepatitis B virus-related hepatocellularcarcinoma in childhood. Hepatology 13:316–320

    Article  PubMed  CAS  Google Scholar 

  • Chang MH, Chen TH, Hsu HM et al (2005) Problems in the prevention of childhood hepatocellular carcinoma in the era of universal hepatitis B immunization. Clin Cancer Res 11:7953–7957

    Article  PubMed  CAS  Google Scholar 

  • Chang MH, Hsu HC, Lee CY et al (1984) Fraternal hepatocellular carcinoma in young children in two families. Cancer 53:1807–1810

    Article  PubMed  CAS  Google Scholar 

  • Chang MH, Hsu HY, Huang LM et al (1996) The role of transplacental hepatitis B core antibody in the mother-to-infant transmission of hepatitis B virus. J Hepatol 24:674–679

    Article  PubMed  CAS  Google Scholar 

  • Chang MH, Shau WY, Chen CJ et al (2000) The effect of universal hepatitis B vaccination on hepatocellular carcinoma rates in boys and girls. JAMA 284:3040–3042

    Article  PubMed  CAS  Google Scholar 

  • Chang MH, You SL, Chen CJ et al (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101:1348–1355

    Article  PubMed  CAS  Google Scholar 

  • Chang MH, You SL, Chen CJ et al (2016) Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151:472–480

    Article  PubMed  CAS  Google Scholar 

  • Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65–73

    Article  PubMed  CAS  Google Scholar 

  • Chen CL, Yang HI, Yang WS et al (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135:111–121

    Article  PubMed  CAS  Google Scholar 

  • Chen DS, Hsu NHM, Sung JL et al (1987) A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 257:2597–2603

    Article  PubMed  CAS  Google Scholar 

  • Chen HL, Chang MH, Ni YH et al (1996) Seroepidemiology of hepatitis B virus infection in children: ten years after a hepatitis B mass vaccination program in Taiwan. JAMA 276:906–908

    Article  PubMed  CAS  Google Scholar 

  • Chen HL, Lin LH, Hu FC et al (2012) Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 142:773–781

    Article  PubMed  Google Scholar 

  • Chen HL, Lee CN, Chang CH et al (2015) Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 62:375–386

    Article  PubMed  CAS  Google Scholar 

  • Chen YC, Chu CM, Liaw YF (2010) Age- specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 51:435–444

    Article  PubMed  Google Scholar 

  • Chien MC, Tong MJ, Lo KJ et al (1981) Hepatitis B viral markers in patients with primary hepatocellular carcinoma in Taiwan. J Natl Cancer Inst 66:475–479

    PubMed  CAS  Google Scholar 

  • Coffin CS, Lee SS (2015) New paradigms in hepatitis B management: only diamonds are forever. Br Med Bull 116:79–91

    PubMed  CAS  Google Scholar 

  • Chua HH, Tsuei DJ, Lee PH et al (2015) RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma. Hepatology 62:1480–1496

    Article  PubMed  CAS  Google Scholar 

  • Da Villa G, Picciottoc L, Elia S et al (1995) Hepatitis B vaccination: Universal vaccination of newborn babies and children at 12 years of age versus high risk groups: a comparison in the field. Vaccine 13:1240–1243

    Article  PubMed  Google Scholar 

  • Egner PA, Wang JB, Shu YR et al (2001) Chlorophyline intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci USA 98:14601–14606

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Grisham JW (2001) Molecular genetic alterations in primary hepatocellular neoplasms. In: Coleman WB, Tsongalis GJ (eds) The molecular basis of human cancer. Humana Press, Totowa, NJ, pp 269–346

    Google Scholar 

  • Halsey NA, Duclos P, van Damme P et al (1999) Hepatitis B vaccine and central nervous system demyelinating diseases. Pediatrc Infect Dis J 18:23–24

    Article  CAS  Google Scholar 

  • Han GR, Cao MK, Zhao W et al (2011) A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 55:1215–1221

    Article  PubMed  CAS  Google Scholar 

  • Heyward WL, Lanier AP, Bender TR et al (1981) Primary hepatocellular carcinoma in Alaskan Natives, 1969–1979. Int J Cancer 28:47–50

    Article  PubMed  CAS  Google Scholar 

  • Hosaka T, Suzuki F, Kobayashi M et al (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98–107

    Article  PubMed  CAS  Google Scholar 

  • Hsu HC, Lin WS, Tsai MJ (1983) Hepatitis B surface antigen and hepatocellular carcinoma in Taiwan. With special reference to types and localization of HBsAg in the tumor cells. Cancer 52:1825–1832

    Article  PubMed  CAS  Google Scholar 

  • Hsu HY, Chang MH, Chen DS et al (1986) Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 18:301–307

    Article  PubMed  CAS  Google Scholar 

  • Hsu HY, Chang MH, Hsieh KH et al (1992) Cellular immune response to hepatitis B core antigen in maternal-infant transmission of hepatitis B virus. Hepatology 15:770–776

    Article  PubMed  CAS  Google Scholar 

  • Hsu HY, Chang MH, Liaw SH et al (1999) Changes of hepatitis B surface variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30:1312–1317

    Article  PubMed  CAS  Google Scholar 

  • Hsu HY, Chang MH, Ni YH et al (2010) Twenty-year trends in the emergence of hepatitis B surface antigen variants in children and adolescents after universal vaccination in Taiwan. J Infect Dis 201:1192–1200

    Article  PubMed  Google Scholar 

  • Hsu YC, Ho HJ, Lee TY et al (2018) Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat. 25:543–551

    Article  PubMed  CAS  Google Scholar 

  • Hsu HY, Chang MH, Ni YH, Chen HL (2004) Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination program in Taiwan. Gut 53:1499–1503

    Google Scholar 

  • International Agency for Research on Cancer, World Health Organization (2018) Cancer today. http://gco.iarc.fr/today/fact-sheets-cancers. Accessed December 29, 2018

  • Jacobson LP, Zhang BC, Shu YR et al (1997) Oltipratz chemoprevention trial in Qidong, People’s Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 6:257–265

    PubMed  CAS  Google Scholar 

  • Jang MK, Lee JY, Lee JH et al (2001) Seroepidemiology of HBV infection in South Korea, 1995 through 1999. Korean J Intern Med 16:153–159

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jee SH, Ohrr H, Sull JW et al (2004) Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 96:1851–1855

    Article  PubMed  Google Scholar 

  • Kane MA (1996) Global status of hepatitis B immunization. Lancet 348:696

    Article  PubMed  CAS  Google Scholar 

  • Kane MA, Brooks A (2002) New immunization initiatives and progress toward the global control of hepatitis B. Current Opinion in Infectious Diseases 15:465–469

    Article  PubMed  Google Scholar 

  • Kapoor R, Kottilil S (2014) Strategies to eliminate HBV infection. Future Virol 9:565–585

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lai CL, Yuen MF (2013) Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 57:399–408

    Article  PubMed  CAS  Google Scholar 

  • Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 11:97–107

    Google Scholar 

  • Lavanchy D (2008) Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 22:991–1008

    Google Scholar 

  • Lee PC, Yeh CM, Hu YW et al (2016) Antiplatelet therapy is associated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection. Ann Surg Oncol 23(Suppl 5):874–883

    Article  PubMed  Google Scholar 

  • Lee SD, Lo KJ, Wu JC et al (1986) Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 6:369–373

    Article  PubMed  CAS  Google Scholar 

  • Liaw YF, Sung JJ, Chow WC et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521–1531

    Article  PubMed  CAS  Google Scholar 

  • Liaw YF (2013) Impact of therapy on the long-term outcome of chronic hepatitis B. Clin Liver Dis 17:413–423

    Article  PubMed  Google Scholar 

  • Lin HH, Chang MH, Chen DS et al (1991) Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: Analysis of prophylaxis failure. Vaccine 9:457–460

    Article  PubMed  CAS  Google Scholar 

  • Lin HH, Lee TY, Chen DS et al (1987) Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis intrauterine infection with hepatitis B virus. J Pediatr 111:877–881

    Article  PubMed  CAS  Google Scholar 

  • Lin SM, Yu ML, Lee CM et al (2007) Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46:45–52

    Article  PubMed  CAS  Google Scholar 

  • Livingston SE, Simonetti J, McMahon B et al (2007) Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 195(5–11):1

    Google Scholar 

  • McMahon BJ, Bulkow LR, Singleton RJ et al (2011) Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 Years after a hepatitis B newborn and catch-up immunization program. Hepatology 54:801–807

    Article  PubMed  Google Scholar 

  • Miyake Y, Kobashi H, Yamamoto K (2009) Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 44:470–475

    Article  PubMed  CAS  Google Scholar 

  • Montesano R (2011) Preventing primary liver cancer: the HBV vaccination project in the Gambia (West Africa). Environmental Health 10(Suppl 1):S6

    Article  PubMed  PubMed Central  Google Scholar 

  • Ni YH, Chang MH, Hsu HY et al (1991) Hepatocellular carcinoma in childhood. Clinical manifestations and prognosis. Cancer 68:1737–1741

    PubMed  CAS  Google Scholar 

  • Ni YH, Chang MH, Huang LM et al (2001) Hepatitis B virus infection in children and adolescents in an hyperendemic area: 15 years after universal hepatitis B vaccination. Ann Intern Med 135:796–800

    Article  PubMed  CAS  Google Scholar 

  • Ni YH, Huang LM, Chang MH et al (2007) Two decades of universal hepatitis B vaccination in Taiwan: Impact and implication for future strategies. Gastroenterology 132:1287–1293

    Article  PubMed  Google Scholar 

  • Ni YH, Chang MH, Jan CF et al (2016) Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan. Clin Gastroenterol Hepatol 14:1324–1330

    Article  PubMed  Google Scholar 

  • Papatheodoridis GV, Idilman R, Dalekos GN et al (2017) The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in caucasians with chronic hepatitis B. Hepatology 66:1444–1453

    Article  PubMed  CAS  Google Scholar 

  • Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156

    Article  PubMed  CAS  Google Scholar 

  • Poovorawan Y, Sanpavat S, Pongpunlert W et al (1989) Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 261:3278–3281

    Article  PubMed  CAS  Google Scholar 

  • Schafer DF, Sorrell MF (1999) Hepatocellular carcinoma. Lancet 353:1253–1257

    Article  PubMed  CAS  Google Scholar 

  • Serigado JM, Izzy M, Kalia H (2017) Novel therapies and potential therapeutic targets in the management of chronic hepatitis B. Eur J Gastroenterol Hepatol 29:987–993

    Google Scholar 

  • Shepard CW, Simard EP, Finelli L et al (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28:112–125

    Article  PubMed  Google Scholar 

  • Sherman M (2013) Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma? Hepatology 58:18–20

    Article  PubMed  Google Scholar 

  • Stevens CE, Beasley RP, Tsui J et al (1975) Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 292:771–774

    Article  PubMed  CAS  Google Scholar 

  • Su TH, Hu TH, Chen CY et al (2016) C-TEAM study group and the Taiwan Liver diseases consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 36:1755–1764

    Article  PubMed  CAS  Google Scholar 

  • Tang JR, Hsu HY, Lin HH et al (1998) Hepatitis B surface antigenemia at birth: a longterm follow-up study. J Pediatr 133:374–377

    Article  PubMed  CAS  Google Scholar 

  • Thursz MR (2014) Treating chronic hepatitis with antiviral drugs to prevent liver cancer. In: Steward Bernard W, Wild Christopher P (eds) World cancer report 2014. WHO, IARC, pp 587–593

    Google Scholar 

  • Tseng TC, Liu CJ, Yang HC et al (2012) High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenteorlogy 142:1140–1149

    Article  CAS  Google Scholar 

  • Turati F, Edefonti V, Talamini R et al (2012) Family history of liver cancer and hepatocellular carcinoma. Hepatology 55:1416–1425

    Article  PubMed  Google Scholar 

  • Van Herck K, Vorsters A, Van Damme P (2008) Prevention of viral hepatitis (B and C) reassessed. Best Pract Res Clin Gastroenterol 22:1009–1029

    Article  PubMed  Google Scholar 

  • van Zonneveld M, van Nunen AB, Niesters HG et al (2003) Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 10:294–297

    Article  PubMed  Google Scholar 

  • Villanueva A, Newell P, Chiang DY et al (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76

    Article  PubMed  CAS  Google Scholar 

  • Wang HC, Huang W, Lai MD et al (2006) Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 97:683–688

    Article  PubMed  CAS  Google Scholar 

  • Whittle H, Jaffar S, Wansbrough M et al (2002) Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325:569–573

    Article  PubMed  PubMed Central  Google Scholar 

  • Wichajarn K, Kosalaraksa P, Wiangnon S (2008) Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 9:507–509

    PubMed  Google Scholar 

  • Wong GL, Yiu KK, Wong VW et al (2010) (2010) Metaanalysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 32:1059–1068

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization (2017) Global hepatitis report 2017. Geneva, Switzerland

    Google Scholar 

  • World Health Organization (2019). (https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed January, 2019

  • Wu CY, Chen YJ, Ho HJ et al (2012) (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308:1906–1914

    Article  PubMed  CAS  Google Scholar 

  • Wu CY, Lin JT, Ho HJ et al (2014) Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 147:143–151

    Article  PubMed  CAS  Google Scholar 

  • Xu WM, Cui YT, Wang L et al (2009) Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 16:94–103

    Article  PubMed  Google Scholar 

  • Yang HI, Lu SN, Liaw YF et al (2002) Hepatitis B e antigen and the risks of hepatocellular carcinoma. N Engl J Med 347:168–174

    Article  PubMed  CAS  Google Scholar 

  • Yang N, Bertoletti A (2016) Advances in therapeutics for chronic hepatitis B. Hepatol Int 10:277–285

    Article  PubMed  Google Scholar 

  • Yang YF, Zhao W, Zhong YD et al (2009) Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 16:265–271

    Article  PubMed  Google Scholar 

  • Yeh SH, Chen PJ (2012) Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 78(suppl 1):172–179

    Google Scholar 

  • Yu MW, Hsu FC, Sheen IS et al (1997) Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 145:1039–1047

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The work was supported by the Yuanta Foundation, Taiwan, and the National Health Research Institute, Taiwan.

Author information

Authors and Affiliations

  1. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

    Mei-Hwei Chang

Authors
  1. Mei-Hwei Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mei-Hwei Chang .

Editor information

Editors and Affiliations

  1. School of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    T.-C. Wu

  2. Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

    Mei-Hwei Chang

  3. Molecular Virology Section, Laboratory of Mole, National Institute of Allergy and Infect, Bethesda, MD, USA

    Kuan-Teh Jeang

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chang, MH. (2021). Prevention of Hepatitis B Virus Infection and Liver Cancer. In: Wu, TC., Chang, MH., Jeang, KT. (eds) Viruses and Human Cancer. Recent Results in Cancer Research, vol 217. Springer, Cham. https://doi.org/10.1007/978-3-030-57362-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-57362-1_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-57361-4

  • Online ISBN: 978-3-030-57362-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation